Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.

European urology - 1 Mar 2016

Groenendijk Floris H, de Jong Jeroen, Fransen van de Putte Elisabeth E, Michaut Magali, Schlicker Andreas, Peters Dennis, Velds Arno, Nieuwland Marja, van den Heuvel Michel M, Kerkhoven Ron M, Wessels Lodewijk F, Broeks Annegien, van Rhijn Bas W G, Bernards René, van der Heijden Michiel S

Abstract excerpt

UNLABELLED: A pathologic complete response to neoadjuvant chemotherapy (NAC) containing platinum is a strong prognostic determinant for patients with muscle-invasive bladder cancer (MIBC). Despite comprehensive molecular characterization of bladder cancer, associations of molecular alterations with treatment response are still largely unknown. We selected pathologic complete responders (ypT0N0; n=38) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoadjuvant Therapy

Share to Neoplasm Invasiveness

Share to Neoplasm Recurrence, Local

Share to Patient Selection

Share to Receptor, ErbB-2

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 25636205
DOI: 10.1016/j.eururo.2015.01.014

Genes

ERBB2
ERCC2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.PMID 25636205Read ↗

Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder CancerSemantic proximity Read ↗

Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.Semantic proximity Read ↗

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.Semantic proximity Read ↗

Exploring vertical genomic heterogeneity and chemotherapy response using targeted genomic sequencing in muscle-invasive bladder cancerSemantic proximity Read ↗

Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.Semantic proximity Read ↗

BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients.Semantic proximity Read ↗

Actionable mutations in muscle-invasive bladder cancer.Semantic proximity Read ↗

Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy.Semantic proximity Read ↗

Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial.Semantic proximity Read ↗

Resistance to Platinum-Based Chemotherapy in Muscle-Invasive Bladder Cancer: Genetic and Immune Determinants and Implications for Treatment Sequencing — A Case SeriesSemantic proximity Read ↗

Mutational Status is Associated with a Higher Rate of Pathologic Complete Response After Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer.Semantic proximity Read ↗

Prediction of Response to Cisplatin-Based Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer Patients by Molecular Subtyping including KRT and FGFR Target Gene AssessmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.